Takeda Pharmaceutical Co Ltd ADR (TAK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $68.47B
Last updated: Nov 17, 2026 at 11:06 AM ET
Takeda Pharmaceutical Co Ltd ADR (TAK) Financials: Revenue, Profit and Cash Flow
Takeda Pharmaceutical Co Ltd ADR reported revenue of JPY 4.78T for the fiscal year ended Mar 31, 2026, up 4.3% from the year before. That year, net income was JPY 203.33B with a net margin of 4.3%, operating cash flow was JPY 1.04T and free cash flow was JPY 626.77B. The quarter ended Sep 30, 2026 had revenue of JPY 1.19T and net income of JPY 192.43B.
Revenue and Margins
The operating margin was 12.0% in the fiscal year ended Mar 2026. Over the 9 years to Mar 2026, revenue grew from JPY 1.73T, a compound annual rate of 12.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | 4.78T | +4.3% | 51.1% | 12.0% | 4.3% |
| Mar 2025 | 4.58T | +7.5% | 65.5% | 7.5% | 2.4% |
| Mar 2024 | 4.26T | +5.9% | 66.4% | 5.0% | 3.4% |
| Mar 2023 | 4.03T | +12.8% | 69.1% | 12.2% | 7.9% |
| Mar 2022 | 3.57T | +11.6% | 69.0% | 12.9% | 6.4% |
| Mar 2021 | 3.20T | -2.8% | 68.9% | 15.9% | 11.8% |
| Mar 2020 | 3.29T | +56.9% | 66.9% | 3.1% | 1.3% |
| Mar 2019 | 2.10T | +18.5% | 68.5% | 9.8% | 5.2% |
| Mar 2018 | 1.77T | +2.2% | 72.0% | 13.7% | 10.6% |
| Mar 2017 | 1.73T | N/A | 67.7% | 9.0% | 6.6% |
Income Statement
In the fiscal year ended Mar 2026, net income rose 88.4% from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.78T | 4.58T | 4.26T | 4.03T | 3.57T | 3.20T | 3.29T | 2.10T | 1.77T | 1.73T |
| Cost of revenue | 2.34T | 1.58T | 1.43T | 1.24T | 1.11T | 994.31B | 1.09T | 659.69B | 495.92B | 558.75B |
| Gross profit | 2.44T | 3.00T | 2.83T | 2.78T | 2.46T | 2.20T | 2.20T | 1.44T | 1.27T | 1.17T |
| Research and development | 716.69B | 730.23B | 729.92B | 633.33B | 526.09B | 455.83B | 492.38B | 368.30B | 325.44B | 312.30B |
| Operating income | 573.04B | 342.59B | 214.07B | 490.50B | 460.84B | 509.27B | 100.41B | 204.97B | 241.79B | 155.87B |
| Net income | 203.33B | 107.93B | 144.07B | 317.02B | 230.06B | 376.00B | 44.24B | 109.13B | 186.89B | 114.94B |
| EBITDA | 1.38T | 1.21T | 1.23T | 1.28T | 1.18T | 983.72B | 671.90B | 464.22B | 359.96B | 296.88B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.19T | 1.22T | 1.11T | 1.21T | 1.11T | 1.11T | 1.05T | 1.14T | 1.18T | 1.21T | 1.05T | 1.11T |
| Gross profit | 795.00B | 813.22B | 543.81B | 660.35B | 732.74B | 722.01B | 671.30B | 727.25B | 781.73B | 821.04B | 663.54B | 731.71B |
| Operating income | 205.32B | 201.42B | 47.54B | 194.06B | 69.00B | 184.57B | -74.90B | 66.94B | 184.25B | 166.33B | -10.07B | 104.91B |
| Net income | 192.43B | 113.20B | -24.77B | 105.51B | -11.80B | 124.24B | -103.20B | 23.79B | 92.05B | 95.25B | -3.02B | 105.72B |
Balance Sheet
As of Mar 2026, total debt of JPY 4.88T exceeded cash and equivalents by 4.29T.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 15.52T | 14.25T | 15.11T | 13.96T | 13.18T | 12.91T | 12.82T | 13.87T | 4.11T | 4.36T |
| Current assets | 3.10T | 2.52T | 2.56T | 2.40T | 2.59T | 2.71T | 2.47T | 3.05T | 1.08T | 1.26T |
| Cash and equivalents | 597.63B | 385.11B | 457.80B | 533.53B | 849.70B | 966.22B | 637.61B | 702.09B | 294.52B | 319.45B |
| Total liabilities | 7.71T | 7.31T | 7.83T | 7.60T | 7.49T | 7.74T | 8.09T | 8.71T | 2.09T | 2.41T |
| Short-term debt | 514.38B | 548.94B | 367.25B | 339.60B | 203.99B | 22.15B | 586.82B | 984.95B | 18.00M | 545.03B |
| Long-term debt | 4.37T | 3.97T | 4.48T | 4.04T | 4.14T | 4.61T | 4.51T | 4.77T | 985.64B | 599.86B |
| Shareholder equity | 7.81T | 6.94T | 7.27T | 6.35T | 5.68T | 5.17T | 4.72T | 5.16T | 2.00T | 1.89T |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 15.27T | 15.66T | 15.52T | 15.42T | 14.47T | 14.00T | 14.25T | 15.11T | 14.57T | 16.23T | 15.11T | 14.22T |
| Total liabilities | 7.85T | 8.10T | 7.71T | 7.77T | 7.34T | 7.14T | 7.31T | 7.69T | 7.65T | 8.43T | 7.83T | 7.48T |
| Cash and equivalents | 418.53B | 460.98B | 597.63B | 655.38B | 681.49B | 350.01B | 385.11B | 494.13B | 859.01B | 804.27B | 457.80B | 288.36B |
| Shareholder equity | 7.42T | 7.56T | 7.81T | 7.65T | 7.13T | 6.87T | 6.94T | 7.42T | 6.92T | 7.80T | 7.27T | 6.74T |
Cash Flow
In the fiscal year ended Mar 2026, free cash flow was 60.3% of operating cash flow. Dividends came to 49.8% of it.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.04T | 1.06T | 716.34B | 977.16B | 1.12T | 1.01T | 669.75B | 328.48B | 377.85B | 261.36B |
| Capital expenditures | 414.66B | 379.63B | 480.73B | 633.69B | 186.04B | 236.47B | 217.71B | 134.11B | 128.26B | 112.03B |
| Free cash flow | 626.77B | 677.56B | 235.61B | 343.47B | 937.07B | 774.46B | 452.04B | 194.37B | 249.59B | 149.34B |
| Dividends paid | 311.90B | 302.50B | 287.19B | 279.42B | 283.67B | 283.36B | 282.58B | 142.95B | 141.89B | 141.69B |
| Investing cash flow | -369.14B | -367.06B | -463.86B | -607.10B | -198.13B | 393.53B | 292.12B | -2.84T | -93.34B | -655.69B |
| Financing cash flow | -496.82B | -751.42B | -354.42B | -709.15B | -1.07T | -1.09T | -1.01T | 2.95T | -326.23B | 289.90B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 257.18B | 127.62B | 74.53B | 373.25B | 378.23B | 215.42B | 222.16B | 383.76B | 280.96B | 170.30B | 278.59B | 146.45B |
| Capital expenditures | 44.54B | 53.81B | 64.39B | 222.37B | 52.83B | 75.07B | 92.72B | 56.65B | 92.45B | 153.49B | 64.33B | 77.12B |
| Free cash flow | 212.65B | 73.81B | 10.13B | 150.88B | 325.40B | 140.35B | 129.44B | 327.11B | 188.51B | 16.81B | 214.26B | 69.33B |
Frequently Asked Questions About TAK
What is Takeda Pharmaceutical Co Ltd ADR's annual revenue?
Takeda Pharmaceutical Co Ltd ADR reported revenue of JPY 4.78T for the fiscal year ended Mar 31, 2026.
How fast is Takeda Pharmaceutical Co Ltd ADR's revenue growing?
Revenue was up 4.3% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 5.9%.
Is Takeda Pharmaceutical Co Ltd ADR profitable?
Yes. Takeda Pharmaceutical Co Ltd ADR reported net income of JPY 203.33B for the fiscal year ended Mar 31, 2026, with a net margin of 4.3%.
How much free cash flow does TAK generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of JPY 1.04T minus capital expenditures of JPY 414.66B produced free cash flow of JPY 626.77B.
How much debt does Takeda Pharmaceutical Co Ltd ADR have?
The balance sheet dated Mar 31, 2026 reported long-term debt of JPY 4.37T, short-term debt of JPY 514.38B and cash and equivalents of JPY 597.63B.
TAK pages: Overview, Dividends, Financials, Valuation, Competitors